{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:59:25Z","timestamp":1774317565377,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12282-025-01684-9","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T14:09:59Z","timestamp":1740060599000},"page":"543-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of axillary lymph-node dissection omission on adjuvant abemaciclib eligibility in HR-positive, HER2-negative breast cancer with positive sentinel lymph nodes"],"prefix":"10.1007","volume":"32","author":[{"given":"Kei","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-5001","authenticated-orcid":false,"given":"Kazutaka","family":"Narui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahato","family":"Sasamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Oshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA. 2017;318:918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA"},{"key":"1684_CR2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","volume":"14","author":"T DiSipio","year":"2013","unstructured":"DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(13)70076-7.","journal-title":"Lancet Oncol"},{"key":"1684_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol"},{"key":"1684_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"\u00c1 S\u00e1volt","year":"2017","unstructured":"S\u00e1volt \u00c1, P\u00e9ley G, Polg\u00e1r C, Udvarhelyi N, Rubovszky G, Kov\u00e1cs E, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43:672\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2016.12.011.","journal-title":"Eur J Surg Oncol"},{"key":"1684_CR5","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","volume":"29","author":"C Tinterri","year":"2022","unstructured":"Tinterri C, Gentile D, Gatzemeier W, Sagona A, Barbieri E, Testori A, et al. Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial. Ann Surg Oncol. 2022;29:5732\u201344. https:\/\/doi.org\/10.1245\/s10434-022-11866-w.","journal-title":"Ann Surg Oncol"},{"key":"1684_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12885-017-3361-y","volume":"17","author":"J de Boniface","year":"2017","unstructured":"de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Ryd\u00e9n L, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: The randomized controlled SENOMAC trial. BMC Cancer. 2017;17:379. https:\/\/doi.org\/10.1186\/s12885-017-3361-y.","journal-title":"BMC Cancer"},{"key":"1684_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1.","journal-title":"Lancet"},{"key":"1684_CR8","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987\u201398. https:\/\/doi.org\/10.1200\/JCO.20.02514.","journal-title":"J Clin Oncol"},{"key":"1684_CR9","doi-asserted-by":"publisher","first-page":"e0264637","DOI":"10.1371\/journal.pone.0264637","volume":"17","author":"DR Nelson","year":"2022","unstructured":"Nelson DR, Brown J, Morikawa A, Method M. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS ONE. 2022;17:e0264637. https:\/\/doi.org\/10.1371\/journal.pone.0264637.","journal-title":"PLoS ONE"},{"key":"1684_CR10","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2217\/fon-2022-0310","volume":"18","author":"KM Sheffield","year":"2022","unstructured":"Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol. 2022;18:2667\u201382.","journal-title":"Future Oncol"},{"key":"1684_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.annonc.2022.04.069","volume":"33","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Jin Q, Mittendorf EA, King TA, Curigliano G, Tolaney SM. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib. Ann Oncol. 2022;33:845\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2022.04.069.","journal-title":"Ann Oncol"},{"key":"1684_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103008","volume":"9","author":"SWM Lammers","year":"2024","unstructured":"Lammers SWM, Meegdes M, Vriens IJH, Voogd AC, de Munck L, van Nijnatten TJA, et al. Treatment and survival of patients diagnosed with high-risk HR+\/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study. ESMO Open. 2024;9: 103008. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103008.","journal-title":"ESMO Open"},{"key":"1684_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41416-024-02580-3","volume":"130","author":"T Gaillard","year":"2024","unstructured":"Gaillard T, Piketty J, Feron J-G, Girard N, Pauly L, Gauroy E, et al. Rethinking surgical revisions: Impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib. Br J Cancer. 2024;130:1141\u20138. https:\/\/doi.org\/10.1038\/s41416-024-02580-3.","journal-title":"Br J Cancer"},{"key":"1684_CR14","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/cncr.35136","volume":"130","author":"AD Williams","year":"2024","unstructured":"Williams AD, Ruth K, Shaikh SS, Vasigh M, Pronovost MT, Aggon AA, et al. Should patients with hormone receptor\u2013positive, HER2\u2013negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib? Cancer. 2024;130:1052\u201360. https:\/\/doi.org\/10.1002\/cncr.35136.","journal-title":"Cancer"},{"key":"1684_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryd\u00e9n L, Szulkin R, Reimer T, Kuhn T, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390:1163\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2313487.","journal-title":"N Engl J Med"},{"key":"1684_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jclinpath-2011-200151","volume":"64","author":"B Fernandez","year":"2011","unstructured":"Fernandez B, Paish C, Green A, Lee A, Macmillan D, Ellis I, et al. Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. J Clin Pathol. 2011;64:995\u20131000. https:\/\/doi.org\/10.1136\/jclinpath-2011-200151.","journal-title":"J Clin Pathol"},{"issue":"3","key":"1684_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.radonc.2007.02.001","volume":"82","author":"M Overgaard","year":"2007","unstructured":"Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b & c randomized trials. Radiother Oncol. 2007;82(3):247\u201353. https:\/\/doi.org\/10.1016\/j.radonc.2007.02.001.","journal-title":"Radiother Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01684-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:34:21Z","timestamp":1748586861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01684-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01684-9","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships that may be considered potential competing interests: KN has received honoraria from Eisai, Daiichi Sankyo, Pfizer, Lilly, Takeda, and Kyowa Kirin. His institution received research grants from Taiho, Eisai, Daiichi Sankyo, Chugai, and Lilly. AY has received honoraria from Chugai, Daiichi Sankyo, Eisai, Exact Science, Kyowa Kirin, Lilly, MSD, Medicon, Nihon Medi-Physics, Pfizer, and Takeda. TI has received honoraria from Daiichi Sankyo, Kirin, Pfizer, Chugai, Lilly, and AstraZeneca. All the remaining authors have declared no conflict of interest associated with this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}